Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515032 | 1.00 | MGLL (0.43) | MGLLSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL4776003 | 0.85 | MGLL (0.48) | MGLL | |
| SCHEMBL3088285 | 0.84 | MCL1 (0.46) | — | |
| SCHEMBL5172182 | 0.84 | MCL1 (0.46) | — | |
| SCHEMBL3518717 | 0.84 | HPGD (0.51) | SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL5339926 | 0.84 | TDP1 (0.48) | SLC6A2SLC6A3 | |
| SCHEMBL3518713 | 0.84 | HPGD (0.51) | SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL3515528 | 0.81 | LMNA (0.53) | MGLLKMT2A | |
| SCHEMBL4776118 | 0.81 | KDM2B (0.51) | MGLLSLC6A2SLC6A3MEN1MAPK1 | |
| SCHEMBL3515523 | 0.81 | LMNA (0.53) | MGLLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | MGLL 4184/4885SLC6A2 3752/4885SLC6A4 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.